470. Clinical Effectiveness of The Monoclonal Antibody Combination Tixagevimab-Cilgavimab (T/C) as Pre-Exposure Prophylaxis (PReP) of COVID-19 among Patients (pts) with Moderate to...

por Haidar, Ghady, Ludwig, Justin, Yealy, Donald M, Camacho, Haley, Chinakarn, Tina, Kip, Kevin, Koscumb, Stephen, Marroquin, Oscar, Minnier, Tami, Snyder, Graham M, Woodworth, Chelsea, Ferreira, Cátia, Glasser, Lisa, Heil, Kathleen, Lee, Andrew, Talarico, Carla, Venkatesan, Sudhir, Taylor, Sylvia, McCreary, Erin K, Mellors, John W
Publicado 2023

471. In-Depth Characterization of SARS-CoV-2 Variants Causing Breakthrough COVID-19 Among Hospitalized Immunocompromised (IC) Patients with or without Prior Exposure to Tixagevimab...

por Haidar, Ghady, Jacobs, Jana L, Salese, Erin, Ludwig, Justin, Heaps, Amy, Parikh, Urvi, Sethi, Rahil, Caruso, Lori, Camacho, Haley, Chinakarn, Tina, Edick, Stacey, Fischer, Dawn, Kramer, Kailey Hughes, Lukanski, Amy, Marks, Kiersten, Saenz-Morales, Naomi, Sierra, Sara, Ferreira, Cátia, Glasser, Lisa, Heil, Kathleen, Talarico, Carla, Taylor, Sylvia, McCreary, Erin K, Mellors, John W
Publicado 2023